Removing the B (cell) STING to improve cancer immunotherapy

作者
Rajan Venkatraman,Dominic De Nardo
出处
期刊:Immunology and Cell Biology [Wiley]
卷期号:100 (10): 753-756 被引量:1
标识
DOI:10.1111/imcb.12601
摘要

Cancer immunotherapies focus on harnessing the host's own immune system to identify and eliminate tumors. One current strategy is to boost the immune system by activating the pattern recognition receptor, Stimulator of Interferon Genes (STING). STING is well known to induce a potent type I interferon (IFN) response as part of the host innate immune response to infection,1 which has been exploited to great effect in antitumor immunity in mouse models.2, 3 However, the development of tumor resistance to STING agonist monotherapy has hampered current efforts to utilize STING activation to treat cancer successfully in humans. Why STING agonists have not yet been clinically successful as originally touted has remained a mystery. In their recent Nature research article, Li et al. shed new light on the use of STING agonists in cancer therapy by identifying a potential mechanism through which STING activation in vivo can actually dampen the antitumor response rather than boost it.4 Immunotherapies enhance our immune system's capacity to recognize and eliminate cancer cells. However, the selection of low immunogenic tumor cells over time can lead to the formation of “cold” tumors, which can no longer be recognized by the immune system. In addition, tumors can remodel their surrounding tissue and extracellular matrix to establish an immunosuppressive milieu that promotes immune evasion.5 Often, the immunosuppressive tumor microenvironment (TME) recruits regulatory B and T cells (Breg and Treg cells, respectively) and myeloid-derived suppressor cells (MDSCs), which suppress the immune system and promote tumor progression. This can be achieved through several mechanisms, including the production of anti-inflammatory molecules, overexpression of checkpoint molecules (e.g. PD-L1) and co-inhibitory molecules, which act to prevent infiltration, proliferation and dampen the effector functions of key immune cells, such as T cells and natural killer (NK) cells.5 Currently, the agreed consensus on the role of STING activation in antitumor immunity is that STING activation in dendritic cells (DCs) increases DC maturation. This subsequently promotes the cross-presentation of tumor antigens to cytotoxic CD8+ T cells and, as a result, increases CD8+ T cell-mediated cytotoxic killing of tumor cells.2, 6, 7 Recent studies have further identified that NK cells can mediate potent tumor elimination in a STING-dependent manner in the absence of CD8+ T cells.8, 9 Since there is limited understanding of how the cGAS-STING pathway primes NK cells-dependent antitumor immunity, most studies have focused on potential T cell-dependent tumor resistance to STING agonist monotherapy, including STING activation leading to T cell death,10 enhanced PD-L1 expression in tumor cells11 and augmented expression of immunosuppressive molecules12 that suppress CD8+ T cell activity. This interesting new work by Li et al.4 identifies that STING activation within immature B cells leads to the development of a subset of Breg cells that dampen NK cell proliferation and cytotoxic activity.4 Systemic administration of the natural STING agonist, cGAMP, into wildtype mice bearing pancreatic ductal adenocarcinoma (PDAC) tumor increased the percentage of B cells among CD45+ intratumoral cells. This was regardless of the number of total CD45+ cells or tumor size, which was surprisingly unaffected by cGAMP treatment, indicating that systemic administration of cGAMP alone in the PDAC model is insufficient to induce antitumor activity. Although the role of T cells in STING antitumor immunity has been extensively examined, there has been limited focus on the role of other lymphocytes, particularly B cells, in fighting cancer. STING activation within B cells has previously been shown to synergistically function with B cell receptor signaling to activate B cells and, thus, humoral immunity.13 However, the role of humoral immunity in fighting cancers has been highly controversial. Here, deletion of Tmem173 (the murine gene encoding STING) reduced the tumor burden when PDAC-bearing mice were treated with cGAMP compared with wildtype mice. While this illustrates that STING activation within B cells is associated with an increased tumor burden, further investigation is required to determine the effect of Tmem173 deletion on B cell development and function in the absence of STING activation as well as B cell tumor infiltration. STING activation has been shown previously to induce several downstream responses including type I IFN response, NF-κB- and MAP kinase-dependent proinflammatory cytokine production, autophagy, cell senescence and various programmed-cell death pathways.1 To understand which aspect of STING signaling within B cells abrogates cGAMP-induced antitumor immunity, Li et al.4 conducted a RNAseq analysis comparing differentially expressed genes between untreated and cGAMP-treated wildtype B cells. Interestingly, interleukin (IL)-10, the cytokine encoded by gene Il10, and Ebi3, a subunit of IL-35 cytokine encoded by gene Ebi3, were upregulated in wildtype B cells following cGAMP treatment. Further investigation revealed that p35 mRNA (another subunit of IL-35; also shared with IL-12) was constitutively expressed and was not altered by cGAMP treatment. This was reflected in the increase of IL-35+ and IL-10+ splenic B cells from wildtype mice treated with cGAMP but not in Tmem173−/− mice. Both IL-10 and IL-35 have been described previously as immunosuppressive cytokines and act as a negative regulator of immune responses.14, 15 While IL-10 has been shown to promote antitumor immunity by dampening tumor-induced inflammation in the TME,14 IL-35 expression promotes the development of tumors, such as PDAC, hepatocellular carcinoma and non-small cell lung cancer.16 While IL-35 can be produced by most immune cells, the major producers of IL-35 are Breg and Treg cells. Interestingly, in a positive-feedback loop, IL-35 is shown to drive the development of conventional B cells and IL-10-producing B cells (also termed B10 cells) into Breg cells.16 In line with these data, Li et al.4 discovered that the IL-35+ B cells displayed the markers phenotypical of murine Breg cells (CD19+CD1dhiCD5+CD21hi). Additionally, cGAMP treatment increased the number of total CD19+CD1dhiCD5+CD21hi Breg cells and the percentage of IL-35+ cells among this Breg cell population. Therefore, STING activation within B cells leads to the development of IL-35+ Breg cells. To further understand the role of IL-10 and IL-35 in the TME, Li et al.4 conducted a correlation analysis that demonstrated that IL-10 and IL-35 expression correlated positively with tumor weight and decreased tumor-infiltrating CD8+, CD4+ and NK1.1+ effector cells. This indicates that both IL-10 and IL-35 are important in establishing an immunosuppressive TME. B cell-specific deletion of Ebi3 or p35 alone increased intratumoral CD8+ T cells and NK cells which indicates that IL-35 plays a major role in suppressing antitumor immune responses within the TME. Intriguingly, cGAMP treatment of these mice did not further increase the number of CD8+ T cells but significantly increased NK cells. This demonstrates that systemic administration of cGAMP drives the development of Breg cells, which attenuates NK tumor infiltration in an IL-35-dependent manner. Cotreatment with an anti-IL-35 antibody (anti-IL-35) and cGAMP had significantly reduced the tumor burden and increased survival.4 Anti-IL-35 and cGAMP dual treatment increased the number of intratumoral NK1.1+ and NK1.1+GzmB+ over each of the mono-treatments alone. Thus, Li et al.4 present a model in which systematic or intratumoral administration of cGAMP induces IL-35 expression in B cells, which dampens NK cytotoxic activity and tumor infiltration leading to tumor resistance to cGAMP monotherapy. However, combinational treatment with anti-IL-35 rescues NK cell activity to overcome tumor resistance (Figure 1). To delineate which aspect of STING signaling was required to induce Il10, Ebi3 and p35 expression in B cells, the authors stimulated splenic B cells isolated from wildtype, Tmem173−/−, Irf3−/− or Ifnar1−/− mice with cGAMP ex vivo and analyzed cells using flow cytometry to quantify the specific IL-35+ and IL-10+ B cell populations. Interestingly, the frequency of IL-35+ and IL-10+ B cells were comparable between Ifnar1−/− and wildtype B cells but markedly diminished in Tmem173−/− and Irf3−/− B cells, thus demonstrating a critical role for IRF3. This was confirmed through IRF3 chromatin immunoprecipitation (ChIP) assays, revealing that IRF3 bound directly to the promoters of p35, Ebi3 and Il10 in wildtype but not Tmem173−/− B cells. This correlated with significant increases in IL-10 and IL-35 cytokine levels in PDAC tumor homogenates. These data demonstrate that p35, Ebi3 and Il10 expression is dependent on STING and IRF3 but independent of type I IFN signaling. This interesting finding highlights our limited understanding of IRF3 as a transcription factor beyond the induction of type I IFNs. Hence, future research is required to understand the effects of non-IFN responses downstream of IRF3 activity within different immune cells. While STING activation has been shown to induce potent antitumor immunity, there are reports of a dichotomous role of STING in cancer progression and immunotherapy. Indeed, STING activation can lead to suppression of T cells by inducing T cell death,10 increased PD-L1 expression11 and expression of immunosuppressive molecules.12 In line with this, the new findings from the Ting laboratory highlight an additional pitfall in the administration of STING agonists in cancer immunotherapy. While this study focused on the effect of cGAMP administration on B cells, these findings can potentially be applied to a more general understanding of the impact of tumor-derived cGAMP on modulating B cell activity in the context of developing tumor resistance. The finding that STING-mediated resistance can be overcome with anti-IL-35 treatment is consistent with observations made by others where IL-35 has been shown to increase tumor burden in PDAC mouse models17 and inversely correlate with the survival of patients with NSCLC.17 Overall, this work further highlights the complex nature of STING activation within the TME and across different immune cells for mediating antitumor immunity. It appears that STING must be very carefully targeted if it is to be effectively exploited for successful cancer immunotherapy. RV is supported by an Australian Government Research Training Program (RTP) Scholarship. DDN is supported in part by a Monash University FMNHS Senior Postdoctoral Fellowship. Rajan Venkatraman: Conceptualization; writing – original draft. Dom De Nardo: Conceptualization; writing – original draft; writing – review and editing. We declare no conflicts of interest.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
左贵辉发布了新的文献求助10
3秒前
molihuakai的应助被W1ndyKnight采纳,获得10
3秒前
思源的应助被W1ndyKnight采纳,获得10
3秒前
充电宝的应助被W1ndyKnight采纳,获得10
3秒前
Chen完成签到,获得积分10
4秒前
小蘑菇的应助被yangYR采纳,获得10
4秒前
张伟发布了新的文献求助10
4秒前
5秒前
鳗鱼铭完成签到,获得积分10
6秒前
6秒前
6秒前
7秒前
ZY完成签到 ,获得积分10
9秒前
天天向上的应助被时平谊采纳,获得10
9秒前
周周发布了新的文献求助50
10秒前
科研通AI6.3的应助被glacier采纳,获得10
10秒前
11秒前
小马甲的应助被薛wen晶采纳,获得10
11秒前
hurys发布了新的文献求助10
12秒前
14秒前
14秒前
syvshc的应助被赵晶晶采纳,获得10
15秒前
大胆的路灯完成签到,获得积分10
15秒前
馍馍发布了新的文献求助30
16秒前
Lee完成签到,获得积分10
16秒前
影zi完成签到 ,获得积分10
18秒前
19秒前
20秒前
theinu完成签到,获得积分10
20秒前
wwwwwwwwww完成签到,获得积分10
20秒前
20秒前
眯眯眼的芷波完成签到,获得积分20
21秒前
21秒前
efwefw完成签到,获得积分10
22秒前
22秒前
Wanfeng完成签到,获得积分10
22秒前
咕噜咕噜完成签到,获得积分10
22秒前
22秒前
传奇3的应助被雯雯采纳,获得10
23秒前
cxy完成签到 ,获得积分10
23秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8186676
求助须知:如何正确求助?哪些是违规求助? 9574945
关于积分的说明 21839037
捐赠科研通 7784275
什么是DOI,文献DOI怎么找? 3434808
关于科研通互助平台的介绍 2559187
邀请新用户注册赠送积分活动 2481611